prev
next

Cardiovascular New Drug
Development Company

bar

About Us

REDNVIA, jointly established with DONG-A ST, is a biotechnology company specializing in cardiovascular diseases.
Our ambition lies not only in drug repurposing but extends to the development of new medicines to innovate cardiovascular therapy.

bar

Pipeline

Calcific Aortic Valve Disease (CAVD) is a disease area of high unmet medical need, currently with no other pharmacotherapy available. REDNVIA is conducting global Phase 2/3 clinical trials in collaboration with numerous world-leading medical institutions and expert researchers to establish a revolutionary treatment paradigm.

  • Calcific Aortic Valve Disease (CAVD)
  • Calcific Aortic Valve Disease (CAVD) is a slow, progressive disorder highly prevalent in the ageing population, ranging from mild valve thickening (i.e. aortic sclerosis) to severe calcification. Patients with severe CAVD suffer from aortic stenosis, which leads to impaired leaflet motion and obstructed blood flow.

Core Competitiveness of REDNVIA

Company

Company+

REDNVIA has undertaken the challenge to develop the world's first drug targeting heart-valve diseases.

Company

RNV-1001

RNV-1001+

RNV-1001 is a clinical project aimed at treating Calcific Aortic Valve Disease (CAVD) by repurposing existing type II diabetes medication. RNV-1001 is currently undergoing Phase 2/3 of global clinical trials.

RNV-1001

Meet Our Team

Meet Our Team+

REDNVIA is led by a group of expert board members widely recognized as key opinion leaders in the medical & health business industry.

Meet Our Team

Patents

Patent+

REDNVIA possesses multiple global patents that are necessary for development in cardiovascular therapeutics.

Patent